170 GSK Annual Report 2018 Notes to the financial statements continued 20.
Investments in associates and joint ventures Joint 2018 Joint 2017 ventures Associates Total ventures Associates Total m m m m m m At 1 January 13 170 183 19 244 263 Exchange adjustments 1 11 12 2 10 12 Additions 1 9 10 15 15 Disposals 92 92 Distributions received 40 40 1 1 2 Other movements 1 39 40 2 2 Profit loss after tax recognised in the consolidated income statement 3 28 31 3 16 13 At 31 December 19 217 236 13 170 183 The Group held one significant associate at 31 December 2018, Innoviva, Inc. At 31 December 2018, the Group owned 32 million shares or 31.7% of Innoviva, which is a biopharmaceutical company listed on NASDAQ.
Innoviva partnered with GSK in the development of the long acting beta agonist vilanterol and currently receives royalty income from sales of products that contain this component, namely Relvar Breo Ellipta and Anoro Ellipta.
It also has a 15% economic interest in royalties paid by GSK on sales of Trelegy Ellipta.
The remaining 85% of the economic interest in these royalties is held by Theravance Biopharma Inc. in which the Group holds 17.4% of the common stock.
The investment in Innoviva had a market value of 440 million at 31 December 2018 2017 336 million.
Summarised balance sheet information, based on published information, in respect of Innoviva is set out below: At 31 December At 31 December 2018 2017 m m Non-current assets 275 124 Current assets 157 148 Current liabilities 4 26 Non-current liabilities 302 426 Net assets liabilities 126 180 2018 2017 m m Interest in associated undertaking 40 57 Goodwill 91 86 Fair value and other adjustments 58 118 Carrying value at 31 December 189 147 21.
Other investments Investments designated as Investments measured at measured at FVTOCI FVTPL 2018 2017 m m m m At 1 January 869 49 918 985 Exchange adjustments 48 4 52 64 Additions 363 9 372 80 Net fair value movements through Other comprehensive income 118 118 11 Net fair value movements through profit or loss 16 16 Impairment losses 30 Disposals and settlements 89 6 95 64 Transfers to Assets held for sale 59 59 At 31 December 1,250 72 1,322 918 Other investments comprise non-current equity investments which are recorded at fair value at each balance sheet date.
For investments traded in an active market, the fair value is determined by reference to the relevant stock exchange quoted bid price.
For other investments, the fair value is estimated by management with reference to relevant available information, including the current market value of similar instruments and discounted cash flows of the underlying net assets.
Other investments include listed investments of 656 million 2017 535 million.
